Irganox 3114 is a hindered phenol antioxidant commonly used to stabilize polymers against degradation caused by oxidation. It is typically incorporated during the polymerization process or added to the final product. The compound is a white to light yellow powder that is soluble in organic solvents but insoluble in water. Its effectiveness as an antioxidant is attributed to its ability to scavenge free radicals that are generated during the oxidation process. This scavenging action helps to prevent the formation of chain reactions that lead to polymer degradation. The study of Irganox 3114 is important in fields like polymer science, materials science, and packaging. It is researched to understand its efficacy in different polymer systems, to optimize its use for different applications, and to explore its potential for improving the durability and longevity of products. Irganox 3114 is a commercially important compound due to its widespread use in various industries, such as plastics, rubber, and adhesives. Research efforts are ongoing to synthesize Irganox 3114 efficiently and develop new antioxidant compounds with improved properties.'
Irganox 3114: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 93115 |
SCHEMBL ID | 31375 |
MeSH ID | M0544061 |
Synonym |
---|
tris(3,5-di-tert-butyl-4-hydroxybenzyl)isocyanurate |
c48h69n3o6 |
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris((3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)methyl)- |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6(1h,3h,5h)-trione |
s-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)- |
einecs 248-597-9 |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazinane-2,4,6-trione |
1,3,5-triazine-2,4,6(1h,3h,5h)-trione, 1,3,5-tris[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]- |
27676-62-6 |
FT-0652727 |
1,3,5-tris[(3,5-ditert-butyl-4-hydroxyphenyl)methyl]-1,3,5-triazinane-2,4,6-trione |
1,3,5-tris[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-1,3,5-triazinane-2,4,6-trione;1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazinane-2,4,6-trione |
A819153 |
680v3mp8yt , |
ec 248-597-9 |
unii-680v3mp8yt |
tris(3,5-di-tert-butyl-4-hydroxybenzyl) isocyanurate |
AKOS015895750 |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)(1,3,5)triazin-2,4,6-trione |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-s-triazinetrione |
plastic additive 6 [usp-rs] |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl) isocyanurate |
1,3,5-tris(4-hydroxy-3,5-di-tert-butylbenzyl)cyanuric acid |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-s-triazine-2,4,6(1h,3h,5h)-trione |
1,3,5-tri(3,5-di-tert-butyl-4-hydroxybenzyl) isocyanurate |
plastic additive 6 |
T3653 |
1,3,5-tris(3,5-di-t-butyl-4-hydroxylbenzyl)-1,3,5-triazine-2,4,6(1h, 3h,5h)-trione |
tris-(3,5-di-tert-butyl-4-hydroxybenzyl)-isocyanurate |
irganox 3114 |
1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-s-triazine-2,4,6(1h,3h, 5h)-trione |
VNQNXQYZMPJLQX-UHFFFAOYSA-N , |
SCHEMBL31375 |
tris-(3,5-di-tert-butyl-4-hydroxybenzyl)isocyanurate |
tris(3,5-di-tert-butyl-4-hydroxybenzyl) isocyanur |
W-107098 |
DTXSID0027935 |
mfcd00134700 |
plastic additive 6, united states pharmacopeia (usp) reference standard |
plastic additive 13, european pharmacopoeia (ep) reference standard |
1,3,5-tris-(3,5-di-t-butyl-4-hydroxybenzyl)isocyanurate |
AS-15297 |
isocyanuric acid tris(3,5-di-tert-butyl-4-hydroxybenzyl) ester |
SB73676 |
Q27264187 |
CS-W011393 |
antioxidant3114 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.29) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |